István Molnár

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet · 2014 · 1.6K citations · Full text

Medicine, Endocrinology, Oncology +11

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

Kathy D. Miller, Javier Cortés, Sara A. Hurvitz et al. · BMC Cancer · 2016 · 160 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Pamela N. Münster, Ian E. Krop, Patricia LoRusso et al. · British Journal of Cancer · 2018 · 126 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Copper deficiency causes reversible myelodysplasia

Jason D. Huff, Yi‐Kong Keung, Mohan C. Thakuri et al. · American Journal of Hematology · 2007 · 95 citations

Medicine, Hematology, Hematopathology +14

Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.

Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · Journal of Clinical Oncology · 2013 · 70 citations

Medicine, Oncology, Endocrine Oncology +7